Demand and usage of unrelated donor products for allogeneic haematopoietic cell transplantation during the COVID-19 pandemic: A Canadian Blood Services Stem Cell Registry analysis

David S. Allan1,2,3 | Meagan Green1 | Gail Morris1 | Jason Weiss1 |
Nicholas Dibdin1 | Dena Mercer1 | Matthew Seftel1,4

1Stem Cells, Canadian Blood Services, Ottawa, Ontario, Canada
2Clinical Epidemiology, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada
3Department of Medicine and Biochemistry, Microbiology & Immunology, Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada
4Department of Medicine, Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada

Correspondence
David S. Allan, The Ottawa Hospital, 501 Smyth Road, Box 704, Ottawa, ON K1H 8L6, Canada. Email: daallan@toh.ca

Funding information
None declared.

Abstract

Background and Objectives: Understanding changes in the demand and usage of unrelated allogeneic haematopoietic cell transplantation (HCT) donors during the COVID-19 pandemic is needed to optimize pandemic preparedness of registry and donor collection services. The aim of this study was to understand the extent to which the pandemic has impacted the demand and usage of unrelated donors and cord blood units (CBUs) at Canadian Blood Services (CBS).

Materials and Methods: Data regarding stem cell donor interest and product usage for unrelated allogeneic HCT were retrieved from the database at CBS using de-identified anonymous information.

Results: Unrelated donor searches for Canadian patients remained unchanged by the pandemic, reflecting stable demand. The number of unrelated allogeneic transplants performed within Canada also remained stable, while the number of cord blood transplants increased, chiefly for paediatric patients. Requests for donor verification typing, a first signal of potential interest, increased from domestic centres during the first 6 months of the pandemic and decreased from international centres, before returning to baseline levels. The proportion of transplants for Canadian patients who used stem cell products procured from Canadian donors increased between 3 and 6 months after the start of the pandemic and decreased from international centres, before returning to baseline levels. The proportion of transplants for Canadian patients who used stem cell products procured from Canadian donors increased between 3 and 6 months after the start of the pandemic before returning to baseline and appears to be increasing again more than 1 year after the start of the pandemic. Use of CBUs for Canadian paediatric patients increased and remains elevated.

Conclusion: Demand for unrelated adult HCT donors has remained stable despite the evolving pandemic with a transient and recurring increased interest and usage of domestic adult donors. Use of CBUs for paediatric patients has increased and remains elevated. Registries and donor collection centres should maintain the capacity to expand services for domestic donor collection during pandemics to offset threats to international donor usage.

Keywords
cord blood, COVID-19, donor usage, haematopoietic cell transplantation, pandemic, unrelated donor
INTRODUCTION

COVID-19 has impacted the procurement of unrelated haematopoietic stem cells for allogeneic transplantation, and transplant centres have undergone significant changes in their approach to selecting donors for haematopoietic cell transplantation (HCT) [1, 2]. Aligning with many other countries [3], transplant centres in Canada initially deferred or delayed transplantation for some patients with non-urgent diagnoses to minimize the potential demand on intensive care units and to avoid hospital capacity crises. In many cases, however, deferring life-saving therapy was not possible, and many centres continued to perform HCT. Indeed, a recent report indicates greater mortality among patients whose transplants were delayed because of the pandemic [4]. Patients with aggressive leukaemias who could not be maintained with additional cycles of chemotherapy represented situations wherein the transplant could not be safely deferred. Moreover, recommendations from the World Marrow Donor Association [5], Cellular Therapy and Transplant Canada [6] and Canadian Blood Services (CBS) Stem Cell Registry [7] strongly encouraged transplant centres to cryopreserve all haematopoietic cell products prior to initiating the preparative regimen before transplant. This allowed the centres to continue with unrelated donor collections and defer the infusion of the cells until a later date, if necessary. Although the impact of the pandemic on adult registries and cord blood banks have been reported [8–10], the impact of COVID-19 on the demand and usage of unrelated donors for Canadian centres has not been described. Given the regional differences in public health measures during the pandemic, understanding the changes in donor usage in Canada is important to optimize services that support patients and transplant centres as the pandemic evolves and to better prepare for possible future threats.

METHODS

Data were retrieved from the Stem Cell National System Solution, which houses prospectively collected data related to the management of donor searches in Canada (excluding the province of Quebec), the unrelated donor Stem Cell Registry, and the public Cord Blood Bank for CBS. Results were analysed in a before-and-after approach using descriptive statistics and considering 15 March 2020 as the initial date of the COVID-19 pandemic. All data were aggregated and anonymized before analysis.

RESULTS

Following the declaration of the global pandemic, new searches for unrelated donors from Canadian transplant centres remained comparable to levels before the pandemic (data not shown), suggesting...
stable demand for unrelated donors. Requests for verification typing (VT), which is the first step in potential donor selection and signals interest in potential donors, also remained stable with an increased proportion of VT requests arising from domestic transplant centres during the first 6 months of the pandemic and reduced levels of VT requests from international centres during the same time period (see Figure 1). VT requests from Canadian and international centres returned to pre-pandemic levels by 6 months after the onset of the pandemic. Work-up requests for Canadian donors, whether initiated by Canadian or international transplant centres, remained stable in the first 6 months of the pandemic (14.8/month) compared to the 6-month period before the pandemic (13.2/month, p = 0.48). However, the proportion of Canadian donor work-ups for Canadian patients increased significantly during the first 6 months of the pandemic (29% before the pandemic vs. 52% post pandemic, respectively, p = 0.003). Moreover, collections occurred in a timely manner following the request to initiate a donor work-up. The mean number of days from work-up initiation to product collection over the 6 months before the pandemic was 45 days (range, 18–172) compared with 37 days (14–139) over the first 6 months of the pandemic. The total number of allogeneic transplants performed in Canada has remained stable at a mean rate of 33 unrelated donor transplants per month throughout the pandemic (data not shown). However, a greater proportion of transplants that used a domestic donor from the CBS Stem Cell Registry increased transiently between 3 and 6 months after the start of the pandemic, with decreased usage of international donors (see Figure 2). Usage of Canadian and international donors for Canadian patients returned to baseline levels after the 6-month mark.

**FIGURE 2** Proportional use of Canadian donors, as opposed to international donors, for Canadian patients, plotted over time. An apparent increase was observed for a brief period of several months starting from 3 months after the onset of the pandemic and may be increasing again in the most recent 3-month period.

**FIGURE 3** Usage of stem cell products from Canadian donors plotted over time. (a) Total number of unrelated donor products collected (black) and number of cord blood units (CBUs) distributed (grey) from Canadian donors. (b) CBUs distributed from the Canadian Blood Services cord blood bank over time to both Canadian (black) and international (grey) transplant centres.
of the pandemic but may be increasing again in the second quarter of 2021 (see Figure 3).

Regarding the procurement of stem cell products from Canadian donors, we observed stable rates of donor collections after the onset of the pandemic compared to pre-pandemic levels (see Figure 3a), except for the first month of the pandemic. The use of cord blood units (CBUs) from the CBS’s Cord Blood Bank for domestic transplant centres (exclusively for paediatric patients) has increased and remained elevated compared to baseline levels (see Figure 3b).

In response to the recommendations from national and international bodies, the majority of products collected from unrelated donors have been cryopreserved (68% of products collected from Canadian donors from March 2020 to June 2021) before infusion in donors have been cryopreserved (68% of products collected from national bodies, the majority of products collected from unrelated donors, more work-up requests in case backup donations were reduction in the use of bone marrow, an increased usage of domestic

The ability to continue with unrelated donor collections during this pandemic reflects the urgent nature of many transplants and the high level of commitment of donors and collection centres to the process of donation. Interest and usage of CBUs from the CBS bank increased substantially, likely reflecting interest in a product that was collected before the pandemic and which is already stored and ready for distribution without the need for a personal courier. Transplant centres may have preferred to organize transplants using cord blood given the increased certainties associated with delivery and scheduling and the predictable high quality of the units [16]. A 7% increase in the usage of CBUs was reported by one European network of banks while banking efforts were stalled during the early stages of the pandemic [10].

Although new collections and banking of CBUs and registration of potential donors at in-person swabbing events were halted during the initial stages of the pandemic, resuming these activities carries increased urgency given our observations of increasing demand. With adaptations to the pandemic, collection and banking of CBUs resumed in Canada within a period of 4 months. Shifting the registration of potential donors to a completely on-line registration process has occurred, which may enhance donor availability at the time of donor activation [17]; however, the effectiveness of this method remains a challenge.

Unrelated donor registries will need to continue to track the trends and challenges related to the ongoing COVID-19 pandemic in order to ensure continued access to high-quality CBUs and unrelated donor products within Canada and abroad. In addition, registries will need to ensure that relevant services such as donor collection facilities and cryopreservation services at cell processing labs remain safely available.

ACKNOWLEDGEMENTS
D.S.A. conceived the study design. M.G., G.M., and J.W. performed data extraction and data analysis. D.S.A. and M.S. were responsible for the initial drafting of the manuscript. All authors were involved in manuscript revisions before final approval.

CONFLICT OF INTEREST
All authors are employed and/or paid consultants at Canadian Blood Services. There are no other conflicts of interest.
REFERENCES

1. Alqwaiz G, Aljurf M, Koh M, Horowitz MM, Ljiangman P, Weisdorf D, et al. Real-world issues and potential solutions in hematopoietic cell transplantation during the COVID-19 pandemic: perspectives from the worldwide network for blood and marrow transplantation and Center for International Blood and Marrow Transplant Research Health Services and International Studies Committee. Biol Blood Marrow Transplant. 2020;26:2181–9.

2. Szer J, Weisdorf D, Querol S, Foeken L, Madrigal A. The impact of COVID-19 on the provision of donor hematopoietic stem cell products worldwide: collateral damage. Bone Marrow Transplant. 2020;55:2043–4.

3. Weinkove R, McQuilten ZK, Adler J, Agar MR, Blyth E, Cheng AC, et al. Managing haematology and oncology patients during the COVID-19 pandemic: interim consensus guidance. Med J Aust. 2020;212:481–9.

4. Nawas MT, Shah GL, Feldman DR, Ruiz JD, Robiliotti EV, Aslam AA, et al. Cellular therapy during COVID-19: lessons learned and preparing for subsequent waves. Transplant Cell Ther. 2021;27:438.e1–6.

5. World Marrow Donor Association. COVID-19 Impact on Registry Operations. Available from: https://share.wmda.info/display/LP/COVID-19+-+Impact+on+Registry+Operations. Accessed 28 Oct 2020.

6. Position Statement on COVID-19 (Latest Revision: Oct 22, 2020). https://www.cttcanada.org/news/535009/Position-Statement-on-COVID-19-Latest-Revision-Oct-22-2020.htm. Accessed 22 Nov 2020.

7. Canadian Blood Services, Stem Cell Registry & Cord Blood Bank, COVID-19 Update. https://share.wmda.info/display/LP/COVID-19+-+Impact+on+Registry+Operations?preview=/344866402/361759428/2020-10-21_Canadian-Blood-Services-Stem-Cells_COVID-19-Update_WMADA%5B1%5D.pdf#COVID-19-ImpactonRegistryOperationsCanadaBloodServicesStemCellRegistry(ION-5103). Accessed 28 Oct 2020.

8. Auletta JJ, Novakovitch JL, Stritesky GL, Newman J, Fridy-Chesser ST, Hailperin K, et al. Meeting the demand for unrelated donors in the midst of the COVID-19 pandemic: rapid adaptations by the National Marrow Donor Program and its network partners ensured a safe supply of donor products. Transplant Cell Ther. 2021;27:133–41.

9. Mengling T, Rall G, Bernas SN, Astreou N, Bochert S, Boelk T, et al. Stem cell donor registry activities during the COVID-19 pandemic: a field report by DKMS. Bone Marrow Transplant. 2021;56:798–806.

10. Rafii H, Ionescu I, Ruggeri F, Garnier F, Ballot C, Bensoussan D, et al. Impact of COVID-19 pandemic on the use and release of cord blood units facilitated by the French Cord Blood Banks Network: on behalf of the Agency of Biomedicine, Eurocord, and the French Society of Bone Marrow Transplant and Cell Therapy (SFGM-TC). Bone Marrow Transplant. 2022;57:125–7.

11. Aziz J, Morris G, Rizk M, Shorr R, Mercer D, Young K, et al. Cryopreservation of adult unrelated donor products in HCT: the OneMatch experience and systematic review of the literature. Transfusion. 2017;57:2782–9.

12. Hsu JW, Farhadfar N, Murthy H, Logan BR, Bo-Subait S, Frey N, et al. The effect of donor graft cryopreservation on allogeneic hematopoietic cell transplantation outcomes: a Center for International Blood and Marrow Transplant Research analysis. Implications during the COVID-19 pandemic. Transplant Cell Ther. 2021;27:507–16.

13. Allan DS. A timely CIBMTR analysis of how cryopreservation impacts allogeneic hematopoietic cell transplantation to apply in the COVID era. Transplant Cell Ther. 2021;27:446–7.

14. Fernandez-Sojo J, Azqueta C, Valdivia E, Martorell L, Medina-Boronat L, Martinez-Llonch N, et al. Cryopreservation of unrelated donor hematopoietic stem cells: the right answer for transplantations during the COVID-19 pandemic? Bone Marrow Transplant. 2021;56:2489–96.

15. Schmidt AH, Buk D, Platz A, van den Brink MRM. Cryopreservation for all is no option in unrelated stem cell transplantation. Transplant Cell Ther. 2020;26:e298–9.

16. Allan D, Kieman J, Dibdin N, Bartlett D, Campbell T, Mostert K, et al. Reducing ethnic disparity in access to high quality HLA-matched cord blood units for transplantation: analysis of the Canadian Blood Services’ Cord Blood Bank inventory. Transfusion. 2019;59:2382–8.

17. Monaghan M, Yi Q-L, Green M, Campbell T, Weiss J, Dibdin N, et al. Factors associated with registrant availability for unrelated adult donor hematopoietic stem cell donation: analysis of the Stem Cell Registry at Canadian Blood Services. Transfusion. 2021;61:24–8.

How to cite this article: Allan DS, Green M, Morris G, Weiss J, Dibdin N, Mercer D, et al. Demand and usage of unrelated donor products for allogeneic hematopoietic cell transplantation during the COVID-19 pandemic: A Canadian Blood Services Stem Cell Registry analysis. Vox Sang. 2022;117:1121–5.